Data From Phase 3 Pivotal Studies Show Amgen’s Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Statin Intolerant Patients And In Patients On Statins

[PR Newswire] – THOUSAND OAKS, Calif., March 30, 2014 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced new detailed data from two Phase 3 pivotal studies that showed treatment with its novel investigational cholesterol-lowering … more

View todays social media effects on AMGN

View the latest stocks trending across Twitter. Click to view dashboard

See who Amgen is hiring next, click here to view